What is the recommended management for Fuchs endothelial dystrophy?

Management of Fuchs Endothelial Dystrophy

For patients with Fuchs endothelial dystrophy requiring surgical intervention, endothelial keratoplasty (EK)—specifically DMEK or DSAEK—is the treatment of choice, with DMEK offering superior visual outcomes and lower rejection rates compared to traditional penetrating keratoplasty. 1

Disease Overview and Staging

Fuchs endothelial dystrophy is a progressive bilateral corneal endothelial disorder characterized by accelerated endothelial cell loss and guttae formation on Descemet's membrane. Patients initially experience transient morning blurred vision that improves throughout the day due to evaporation-induced corneal dehydration. As disease progresses, permanent corneal edema develops, leading to visual impairment from both reduced acuity and disabling glare 1.

Critical clinical point: Visual acuity may not correlate with functional impairment—patients with 20/40 vision may be unable to drive due to glare from higher-order aberrations 1.

Medical Management (Early Disease)

For mild symptomatic disease without significant visual impairment:

• Topical hyperosmotic agents (5% sodium chloride drops/ointment) to facilitate corneal dehydration
• Environmental modifications: Low humidity environments and modest air movement improve symptoms
• Rigid gas-permeable contact lenses can create a smoother refractive surface and improve visual function 1

Surgical Management Algorithm

Primary Surgical Options (Ranked by Outcomes)

The 2024 Ophthalmology guidelines clearly demonstrate that 95% of Fuchs dystrophy patients in the United States are now treated with endothelial keratoplasty rather than penetrating keratoplasty 1.

1. DMEK (Descemet Membrane Endothelial Keratoplasty) - FIRST CHOICE

Best outcomes for visual recovery and graft survival:

• 94% achieve 20/40 or better vision at 6 months (vs. 65-84% at 1 year for PK)
• Visual recovery: 2/3 stable by 3 months (vs. 6-12 months for PK)
• Lowest rejection rates: 2.8% at 5 years (vs. 22% for both PK and DSAEK)
• Minimal refractive shift: +0.24 to +0.32 D hyperopia, no induced astigmatism
• Graft failure at 5 years: 0-12.5% for Fuchs 1

Disadvantages:

• Higher technical difficulty
• Dislocation rate: 5.9-27.4% (though improved with SF6 gas and orientation marking)
• Primary graft failure: 2.2-8.0% 1

Best for: Standard endothelial failure with good anterior chamber visibility

2. DSAEK (Descemet Stripping Automated Endothelial Keratoplasty) - SECOND CHOICE

When DMEK is not feasible:

• Visual outcomes: 38-90% achieve 20/40 or better at 1 year
• Lower dislocation rate: 14.5-15% compared to DMEK
• Rejection rate at 5 years: 22% (similar to PK)
• Induced hyperopia: +1.10 D (range 0.70-1.50 D)—must account for this in IOL calculations
• Graft failure at 5 years: 5% for Fuchs 1

Best for: Decreased anterior chamber visibility, complex situations (previous glaucoma surgery, iris defects), or when surgeon expertise with DMEK is limited 1

Note: Ultrathin DSAEK (<100 μm) shows improved visual recovery compared to standard thickness 1

3. Penetrating Keratoplasty (PK) - RARELY INDICATED

Now reserved for cases with concurrent anterior corneal pathology requiring full-thickness replacement:

• Major disadvantages: 4-6 D induced astigmatism, 6-12 month visual recovery, 22.2% rejection at 5 years, wound dehiscence risk (1.3-5.8%)
• Graft failure at 5 years: 5% for Fuchs 1

Emerging Option: Descemet Stripping Only (DSO)

DSO with Rho-kinase inhibitors shows promise for select patients:

• Corneal clearance rate: 91% overall, 96% with prophylactic ROCKi vs. 85% without (p=0.0012) 2
• Mean time to clearance: 4.9 weeks with ROCKi vs. 10.1 weeks without (p<0.0001) 3
• Secondary EK needed: 10% (considered surgical failure) 2
• Visual improvement: Mean 0.23 LogMAR improvement 2

Patient selection criteria for DSO success:

• 4-mm descemetorhexis size
• Clear peripheral endothelium with no guttae or decompensation
• Low central corneal thickness
• Adequate peripheral endothelial cell count 3

Advantages: Avoids donor tissue dependence, eliminates immunological rejection risk, simpler procedure 2

Current status: Requires further prospective studies to establish standard indications; consider as investigational option in carefully selected patients 2, 4

Combined Cataract Surgery

When cataract coexists with Fuchs dystrophy:

• Perform cataract extraction prior to or simultaneously with EK
• IOL power calculations: DMEK requires minimal adjustment; DSAEK requires accounting for +1.10 D hyperopic shift 1
• Combined procedures are well-tolerated with both DMEK and DSAEK 1

Key Surgical Considerations

DMEK technical advances reducing complications:

• "S" stamp or orientation marking reduces iatrogenic graft failures
• SF6 gas significantly reduces rebubbling rates
• Preloaded DMEK tissue from eye banks simplifies insertion 1

EK advantages over PK:

• Rapid visual recovery
• Greater optical predictability (refractive and astigmatic)
• Smaller, more stable wounds
• Decreased rejection risk
• Better outcomes in patients with ocular surface disease (dry eye, blepharitis) 1

Common Pitfalls

1. Underestimating functional impairment: Don't rely solely on Snellen acuity—assess glare disability and quality of life
2. IOL miscalculation: Account for hyperopic shift with DSAEK (+1.10 D) when planning combined procedures
3. Delaying surgery: Patients with disabling symptoms despite preserved acuity benefit from early intervention
4. Ignoring peripheral endothelium: DSO success depends on adequate peripheral endothelial reserve—not just central pathology

Postoperative Monitoring

Endothelial cell loss over time (DMEK):

• 1 year: 32-34%
• 5 years: 42-48%

This is comparable to DSAEK and significantly better than PK 1